Do not stop talking about Epstein.
Do not stop talking about Epstein.
Do not stop talking about Epstein.
Do not stop talking about Epstein.
Do not stop talking about Epstein.
Do not stop talking about Epstein.
Do not stop talking about Epstein.
DO NOT STOP TALKING ABOUT THE EPSTEIN FILES.
Does anyone else notice that no matter how many folks are posting about the Epstein files, it never trends on X?
KENJIRO TSUDA DEMANDA A TIKTOK
El legendario actor de voz acaba de convertirse en el primer artista de Japón en demandar formalmente a la plataforma por permitir la clonación de su voz mediante Inteligencia Artificial.
Tsuda exige la eliminación inmediata de estos videos generados sin su permiso. Irónicamente, su equipo legal está utilizando los propios comentarios de la aplicación, donde los usuarios celebraban que el audio "suena exactamente como Tsuda", como evidencia irrefutable del plagio ante el Tribunal de Tokio.
Las empresas tecnológicas creyeron que podían comercializar la identidad de los actores de forma gratuita, pero acaban de elegir al peor protagonista posible para intentar silenciar.
A psychiatrist named Jan Fawcett tracked 954 depressed patients. He found that one symptom predicted who would die by suicide within a year, no matter how bad their depression was otherwise: losing interest in everything. Doctors call it anhedonia.
It shows up on brain scans. A small region deep in the brain called the reward center quietly stops working, and the brain releases less dopamine, the chemical that makes things feel good. Around 70 percent of people diagnosed with major depression report this loss of interest. A 2024 review in the International Journal of Neuropsychopharmacology found that patients with anhedonia are much more likely to end up with depression that doesn't respond to medication.
The most prescribed antidepressants often fall short on anhedonia. SSRIs like Prozac, Zoloft, and Lexapro mainly raise serotonin, but anhedonia is mostly a dopamine problem, so the standard prescription is aimed at the wrong chemical.
Four treatments have actual evidence. Ketamine, and a nasal spray version called esketamine approved for stubborn depression, can lift anhedonia in hours. Standard antidepressants take weeks. A 2025 paper in the journal Neuron traced this to specific changes inside the brain's reward center. Behavioral activation therapy, where patients schedule small pleasurable activities and force themselves to do them even when they don't feel like it, slowly teaches the reward center to fire again. Exercise releases a brain-repair protein called BDNF that helps rebuild dopamine pathways over weeks. And a treatment called TMS, which uses magnetic pulses on the front of the brain, has shown strong results in recent trials for anhedonia specifically.
There is also a newer research area called digital anhedonia. Brain scans of heavy social media users show the reward center lights up strongly for notifications and feeds but stays quiet for ordinary pleasures like food, conversations, and walks. The reward bar gets reset so high that normal life cannot reach it.
The brain heals. With proper treatment, many people improve within weeks, and the reward system can rebuild over months. So losing interest in everything is treatable. And the first medication doctors usually prescribe is rarely the one that fixes it.